{
    "clinical_study": {
        "@rank": "16593", 
        "arm_group": {
            "arm_group_label": "bevacizumab", 
            "arm_group_type": "Experimental", 
            "description": "The study evaluate 4 dose level of bevacizumab:2.5mg /kg;5 mg /kg;7.5mg /kg; 1.25mg /kg;"
        }, 
        "brief_summary": {
            "textblock": "Malignant ascites often has a profound impact on the quality of life of cancer patients.\n      Current treatments,including dietary, medical, and procedural are often temporary and\n      unsatisfactory options in patients approaching the end of life. Intraperitoneal bevacizumab\n      for the palliation of malignant ascites might be a novel choice for refractory malignant\n      ascites."
        }, 
        "brief_title": "Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Refractory Malignant Ascites", 
        "condition_browse": {
            "mesh_term": "Ascites"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Signed informed consent form;\n\n          2. Histologically or cytologically confirmed non-squamous cell carcinoma\uff0cincluding\n             colorectal cancer, gastric cancer, esophageal cancer, pancreatic cancer, bile duct\n             cancer, ovarian cancer, peritoneal primary tumor;Ascites were diagnosed by ultrasound\n             or CT and confirmed malignant ascites by cytology;\n\n          3. failed to standard systemic therapy and / or no appropriate treatment for the\n             treatment for malignant ascites\n\n          4. Age 18-70 years;\n\n          5. Performance Status- Eastern Cooperative Oncology Group (ECOG)\u22642;\n\n          6. Life expectancy of at least 8 weeks;\n\n        Exclusion Criteria:\n\n          1. systematic anti-cancer therapy, including chemotherapy (intraperitoneal\n             chemotherapy), radiation therapy, immunotherapy, biological or hormone therapy\n             performed within 2 weeks;\n\n          2. tyrosine kinase inhibitors or monoclonal antibodies of anti-vascular endothelial\n             growth factor (VEGF) performed within 4 weeks;\n\n          3. Laboratory tests:Absolute neutrophil count<1.0x109/L,Platelet count<75x\n             109/L,Hemoglobin<8g/dl,PT-INR\u22651.5 times upper limit of normal (ULN);Bilirubin\u22652 x\n             ULN,AST and ALT\u22652.5 times ULN(no liver metastasis),\u22655 times ULN(with liver\n             metastasis)Creatinine\u22651.5 times ULN or calculated creatinine clearance, using the\n             Cockcroft-Gault formula,<40 mL/min;\n\n          4. uncontrolled hypertension:systolic pressure \u2265160 mmHg,or diastolic pressure\u2265100mmHg\n\n          5. Known history of severe heart disease,uncontrolled or symptomatic angina, congestive\n             heart failure,clinically significant arrhythmias,myocardial infarction within six\n             months;\n\n          6. active (severe or uncontrolled) bleeding (hemorrhage within 3 months> 30 ml),\n             hemoptysis (fresh blood, 4 weeks> 5 ml), bloody ascites\n\n          7. thrombosis, tumor thrombus events (including arterial/venous thrombosis, tumor\n             thrombosis, pulmonary embolism, transient ischemic attack)within 12 months;\n\n          8. Portal hypertensive disease or severe liver disease, including various types of\n             cirrhosis, obstructive jaundice;\n\n          9. concurrent gastrointestinal obstruction, peptic ulcer, Crohn's disease, ulcerative\n             colitis and other gastrointestinal diseases according to investigators' determination\n             that may cause gastrointestinal bleeding or perforation;\n\n         10. concurrent severe respiratory disease, or chronic therapy with oxygen or\n             corticosteroids, such as chronic obstructive pulmonary disease, interstitial lung\n             disease, etc.\n\n         11. Unresolved or unstable, serious toxicity from prior cancer treatment (any toxicities\n             greater than grade 2 or not recovered from surgery;\n\n         12. Symptomatic brain metastasis;\n\n         13. Uncontrolled systemic disease,such as infection,unstable diabetes mellitus,etc;\n\n         14. Active infection of HIV\u3001HBV\u3001HCV\uff1b\n\n         15. Major surgery within 4 weeks of start of study treatment, without complete recovery.\n\n         16. Pregnant or lactating women.Negative serum pregnancy test (For women of childbearing\n             potential);Fertile patients must use effective contraception.\n\n         17. Dementia, altered mental status, or any psychiatric condition that would prevent the\n             understanding or rendering of ICF;\n\n         18. Received any investigational drug treatment within 4 weeks of start of study\n             treatment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01852409", 
            "org_study_id": "CGOG6001"
        }, 
        "intervention": {
            "arm_group_label": "bevacizumab", 
            "intervention_name": "bevacizumab", 
            "intervention_type": "Drug", 
            "other_name": "Avastin"
        }, 
        "intervention_browse": {
            "mesh_term": "Bevacizumab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "refractory malignant ascites", 
            "Bevacizumab", 
            "intraperitoneal", 
            "phase I"
        ], 
        "lastchanged_date": "May 19, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100142"
                    }, 
                    "name": "Beijing Cancer Hospital"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "email": "lin100@medmail.com.cn", 
                    "last_name": "Lin Shen, M.D.", 
                    "phone": "861088196561"
                }, 
                "contact_backup": {
                    "email": "gongjifang@gmail.com", 
                    "last_name": "Jifang Gong, M.D.", 
                    "phone": "861088196561"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100142"
                    }, 
                    "name": "Peking University Cancer Hospital"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites.", 
        "overall_contact": {
            "email": "lin100@medmail.com.cn", 
            "last_name": "Lin Shen, M.D.", 
            "phone": "861088196561"
        }, 
        "overall_contact_backup": {
            "email": "gongjifang@gmail.com", 
            "last_name": "Jifang Gong, M.D.", 
            "phone": "861088196561"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "participants will be followed for the duration of hospital stay, an expected average of 1 week", 
                "measure": "adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "during the treatment in the hospital,an expected average of 1 week"
            }, 
            {
                "description": "during the treatment in the hosptital", 
                "measure": "Maximum tolerated dose", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01852409"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Peking University", 
            "investigator_full_name": "Shen Lin", 
            "investigator_title": "Director of GI oncology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "ultrasound will be performed every week for efficacy evaluation", 
                "measure": "Objective response rate", 
                "safety_issue": "Yes", 
                "time_frame": "1 week"
            }, 
            {
                "description": "the follow-up visit of time to TTF will be performed every 4 weeks", 
                "measure": "time to treatment failure(TTF)", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "description": "TTD means that from the first dose of treatment drug to death or lost, the follow-up visit will be performed every 2 months till death or lost", 
                "measure": "time to death(TTD)", 
                "safety_issue": "No", 
                "time_frame": "2 months"
            }
        ], 
        "source": "Peking University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Peking University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}